Donner
Anti-Obesity Drugs Market Report by Worldwide Market Trends & Opportunities and Forecast to 2035
Owing to the increased prevalence rate of obesity and need for effective drug products, several researchers and industry stakeholders are increasingly shifting their focus towards the development of anti-obesity drugs
Anti-obesity drugs consist of various pharmaceutical treatments aimed at helping individuals manage obesity and related health issues.
The global anti-obesity drugs market size is projected to grow from $12.8 billion in 2024 to $104.9 billion in 2035, representing a CAGR of 21.1%, till 2035.
These medications provide healthcare professionals with valuable tools to complement lifestyle interventions, such as diet and exercise. They play a critical role in enhancing weight loss outcomes, particularly for patients with significant obesity-related comorbidities. Further, these drugs contribute to improved quality of life and potentially lower healthcare costs by preventing complications associated with obesity.
Advancements in drug formulation and delivery systems, along with the integration of novel compounds, have led to the emergence of more effective and safer anti-obesity medications. The increasing focus on personalized medicine and pharmacogenomics further enhances the potential for tailored treatments that address individual patient needs. Additionally, the surge in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment regimens.
Type of Molecule
Biologics
Small Molecules
Active Compound Used
Tirzepatide
Semaglutide
Retatrutide
Survodutide
Cagrilintide and Semaglutide
Orforglipron
Liraglutide
Other Active Compounds
Mechanism of Action
GLP-1 Agonist / GIP Agonist
GLP-1 Agonist / GCGR Agonist
GLP-1 Agonist
GLP-1 Agonist / Amylin Analogue
GLP-1 / GCGR / GIP Agonist
Other Mechanisms of Action
Type of Agonist
Single-Agonist
Dual-Agonist
Tri-Agonist
It is worth highlighting that there is a significant rise in the interest of stakeholders in anti-obesity drugss segment; this can be validated by the increase in activity of big pharma players within this domain. Further, the growing demand for anti-obesity has compelled the players engaged in this domain to expand their existing capabilities / capacities in order to accommodate the future needs of their clients. With a growing emphasis on obesity as a chronic disease requiring long-term management, the anti-obesity drugs market is poised for robust expansion, offering significant opportunities for stakeholders in the coming years.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Agricultural biologicals Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
Sales@rootsanalysis.com
Owing to the increased prevalence rate of obesity and need for effective drug products, several researchers and industry stakeholders are increasingly shifting their focus towards the development of anti-obesity drugs
Anti-obesity drugs consist of various pharmaceutical treatments aimed at helping individuals manage obesity and related health issues.
The global anti-obesity drugs market size is projected to grow from $12.8 billion in 2024 to $104.9 billion in 2035, representing a CAGR of 21.1%, till 2035.
These medications provide healthcare professionals with valuable tools to complement lifestyle interventions, such as diet and exercise. They play a critical role in enhancing weight loss outcomes, particularly for patients with significant obesity-related comorbidities. Further, these drugs contribute to improved quality of life and potentially lower healthcare costs by preventing complications associated with obesity.
Advancements in drug formulation and delivery systems, along with the integration of novel compounds, have led to the emergence of more effective and safer anti-obesity medications. The increasing focus on personalized medicine and pharmacogenomics further enhances the potential for tailored treatments that address individual patient needs. Additionally, the surge in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment regimens.
Type of Molecule
Biologics
Small Molecules
Active Compound Used
Tirzepatide
Semaglutide
Retatrutide
Survodutide
Cagrilintide and Semaglutide
Orforglipron
Liraglutide
Other Active Compounds
Mechanism of Action
GLP-1 Agonist / GIP Agonist
GLP-1 Agonist / GCGR Agonist
GLP-1 Agonist
GLP-1 Agonist / Amylin Analogue
GLP-1 / GCGR / GIP Agonist
Other Mechanisms of Action
Type of Agonist
Single-Agonist
Dual-Agonist
Tri-Agonist
It is worth highlighting that there is a significant rise in the interest of stakeholders in anti-obesity drugss segment; this can be validated by the increase in activity of big pharma players within this domain. Further, the growing demand for anti-obesity has compelled the players engaged in this domain to expand their existing capabilities / capacities in order to accommodate the future needs of their clients. With a growing emphasis on obesity as a chronic disease requiring long-term management, the anti-obesity drugs market is poised for robust expansion, offering significant opportunities for stakeholders in the coming years.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Agricultural biologicals Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
Sales@rootsanalysis.com
Anti-Obesity Drugs Market Report by Worldwide Market Trends & Opportunities and Forecast to 2035
Owing to the increased prevalence rate of obesity and need for effective drug products, several researchers and industry stakeholders are increasingly shifting their focus towards the development of anti-obesity drugs
Anti-obesity drugs consist of various pharmaceutical treatments aimed at helping individuals manage obesity and related health issues.
The global anti-obesity drugs market size is projected to grow from $12.8 billion in 2024 to $104.9 billion in 2035, representing a CAGR of 21.1%, till 2035.
These medications provide healthcare professionals with valuable tools to complement lifestyle interventions, such as diet and exercise. They play a critical role in enhancing weight loss outcomes, particularly for patients with significant obesity-related comorbidities. Further, these drugs contribute to improved quality of life and potentially lower healthcare costs by preventing complications associated with obesity.
Advancements in drug formulation and delivery systems, along with the integration of novel compounds, have led to the emergence of more effective and safer anti-obesity medications. The increasing focus on personalized medicine and pharmacogenomics further enhances the potential for tailored treatments that address individual patient needs. Additionally, the surge in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment regimens.
Type of Molecule
Biologics
Small Molecules
Active Compound Used
Tirzepatide
Semaglutide
Retatrutide
Survodutide
Cagrilintide and Semaglutide
Orforglipron
Liraglutide
Other Active Compounds
Mechanism of Action
GLP-1 Agonist / GIP Agonist
GLP-1 Agonist / GCGR Agonist
GLP-1 Agonist
GLP-1 Agonist / Amylin Analogue
GLP-1 / GCGR / GIP Agonist
Other Mechanisms of Action
Type of Agonist
Single-Agonist
Dual-Agonist
Tri-Agonist
It is worth highlighting that there is a significant rise in the interest of stakeholders in anti-obesity drugss segment; this can be validated by the increase in activity of big pharma players within this domain. Further, the growing demand for anti-obesity has compelled the players engaged in this domain to expand their existing capabilities / capacities in order to accommodate the future needs of their clients. With a growing emphasis on obesity as a chronic disease requiring long-term management, the anti-obesity drugs market is poised for robust expansion, offering significant opportunities for stakeholders in the coming years.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Agricultural biologicals Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
Sales@rootsanalysis.com
0 Commentaires
0 Parts
37 Vue
0 Aperçu
English
Arabic
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek